GlassScriptPhysician profile
Lavonne M Burrows
NPI 1942397310
$4,949.15
in general payments reported to CMS, 2019-2025
28 companies · $1,094 in 2025
The $1,094 reported for 2025 was more than what 93% of Medical-Surgical (Clinical Nurse Specialist) providers received nationally (typical 2025 total: $167).
See the full distribution for Medical-Surgical (Clinical Nurse Specialist)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $637 · 2022: $1,108 · 2023: $1,405 · 2024: $705 · 2025: $1,094.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,201 · Education: $4.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,200.52 |
| Education | $4.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $692.34 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $640.88 | 2022-2025 | Jynarque, Rexulti |
| Travere Therapeutics, INC. | $515.06 | 2023-2025 | Filspari |
| Genzyme Corporation | $324.82 | 2022-2024 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $311.45 | 2021-2025 | Jynarque |
| Vifor Pharma, INC. | $265.12 | 2022 | |
| Neurocrine Biosciences, INC. | $247.37 | 2022-2024 | Ingrezza |
| Akebia Therapeutics INC | $162.29 | 2021-2024 | Vafseo, Auryxia |
| Bayer Healthcare Pharmaceuticals INC. | $157.39 | 2022-2023 | |
| Kyowa Kirin, INC. | $139.99 | 2025 | |
| Glaxosmithkline, LLC. | $129.04 | 2023 | Jesduvroq |
| Janssen Pharmaceuticals, INC | $128.75 | 2023 | Spravato |
| Amgen INC. | $124.99 | 2023 | Repatha |
| Lundbeck LLC | $123.30 | 2023 | Vyepti |
| Dexcom, INC. | $104.57 | 2025 | Dexcom G7 Gss (161), Dexcom Stelo Glucose Biosensor |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nxstage Medical, INC. | $104.30 | 2023 | Nxstage System One |
| Biogen, INC. | $99.86 | 2021 | |
| Jazz Pharmaceuticals INC. | $98.21 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $95.86 | 2022 | |
| Ardelyx, INC. | $94.77 | 2024 | Xphozah 30 Mg |
| Cormedix INC. | $90.46 | 2025 | |
| Baxter Healthcare | $78.34 | 2022-2023 | Renal - Pd |
| Vantive US Healthcare LLC | $72.63 | 2025 | Renal - Pd |
| Fresenius USA Marketing, INC. | $43.79 | 2025 | Velphoro |
| Calliditas Therapeutics US INC. | $38.89 | 2025 | Tarpeyo |
| Novo Nordisk INC | $24.19 | 2025 | Ozempic |
| Horizon Therapeutics Plc | $20.69 | 2022 | |
| Shield Therapeutics INC | $19.80 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lavonne Burrows listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.